MLYS Stock: Price, Earnings History and SEC Filings
Mineralys Therapeutics, Inc. (MLYS) last traded at $18.18, down 14.41% on the latest session and down 27.7% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-2.85 against an analyst estimate of $-0.57, a miss of 400.0%.
$18.18 -14.41%
1 month-27.66%
52-week high$47.65
52-week low$18.11
Volume3.98M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
MLYS earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 11, 2026 | $-2.85 | $-0.57 | -400.00% |
| Mar 2026 | May 6, 2026 | $-0.47 | $-0.51 | +7.84% |
| Dec 2025 | Mar 12, 2026 | $-0.40 | $-0.57 | +29.82% |
| Sep 2025 | Nov 10, 2025 | $-0.52 | $-0.66 | +21.21% |
MLYS beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for MLYS
SEC filing data is not available right now. You can search for MLYS on SEC EDGAR.
MLYS news
- Kidney Trial Results Could Change The Case For Mineralys Therapeutics StockNov 1, 2026 · finance.yahoo.com
- Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026Oct 28, 2026 · finance.yahoo.com
- Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney InternationalOct 28, 2026 · finance.yahoo.com
- Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026Oct 22, 2026 · finance.yahoo.com
- Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel CoatsOct 19, 2026 · finance.yahoo.com
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. (MLYS) is a US-listed public company on Nasdaq.